← Back to Search

Probiotic Therapy

SYNB1618 for Phenylketonuria (SynPheny-1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Synlogic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 43
Awards & highlights

SynPheny-1 Trial Summary

This study is evaluating whether a drug may help treat a genetic disorder.

Eligible Conditions
  • Phenylketonuria

SynPheny-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 43
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 43 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes from baseline in labeled Phe (D5-Phe) in plasma
Secondary outcome measures
Changes from baseline in fasting levels of plasma Phe
Incidence of Treatment-Emergent Adverse Events

SynPheny-1 Trial Design

2Treatment groups
Experimental Treatment
Group I: SYNB1934Experimental Treatment1 Intervention
Dose ramp of SYNB1934
Group II: SYNB1618Experimental Treatment1 Intervention
Dose ramp of SYNB1618
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SYNB1934
2021
Completed Phase 2
~130
SYNB1618
2021
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

SynlogicLead Sponsor
9 Previous Clinical Trials
480 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Apr 2025